NHS National Framework Agreement for Macitentan & Cladribine Tablets
NHS England · published 3 Nov 2026
- Tender expected
- 27 Jan 2027
- Market engagement until
- 17 Nov 2026
- Estimated value
- £128,400,000 excluding VAT where stated
- Procedure
- Procedure not stated · above threshold
- Contract dates
- 1 Oct 2027 to 30 Sept 2029
- Where
- North East, North West and 5 more
- Categories (CPV)
- 33600000 Pharmaceutical products
- Small businesses
- The buyer marks this as suitable for SMEs.
Description
Project title: NHS National Framework Agreement for Macitentan & Cladribine Tablets Offer reference number: CM/TNS/26/5748 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5748/01 Macitentan Lot 1 DCE/DLN: 01/10/2027 to 30/09/2029 (24 months) CELN Lot 2 DNW/DLS: 01/10/2027 to 31/01/2029 (16 months) NWLS Lot 3 DNE/DSW: 01/10/2027 to 30/09/2029 (24 months) NESW CM/TNS/26/5748/02 Cladribine Tablets Lot 1 DCE/DSW: 01/10/2027 to 30/09/2029 (24 months) CESW Lot 2 DLN/DNW: 01/10/2027 to 31/01/2029 (16 months) NWLN Lot 3 DLS/DNE: 01/10/2027 to 30/09/2028 (12 months) LSNE Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Notices for this procurement
- 3 Nov 2026 · Preliminary market engagement notice (update)104326-2026 (opens in a new tab)
- 3 Nov 2026 · Preliminary market engagement notice104267-2026 (opens in a new tab)
Deciding whether to bid?
Upload the tender pack and get a brief with every pass/fail requirement quoted from the documents, the scoring model and the questions you must answer. The first brief is free.